• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    argenx SE - American Depositary Shares (NQ:ARGX)

    847.74 +29.44 (+3.60%)
    Delayed Quote Updated: 12:25 PM EDT, Oct 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about argenx SE - American Depositary Shares

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
    From argenx SE
    Via GlobeNewswire
    News headline image
    ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
    From Schall, Brown & Schwartz LLP
    Via Business Wire
    News headline image
    argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Present at Upcoming Investor Conferences
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Completes Acquisition of Forte Biosciences, Inc.
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
    From Forte Biosciences, Inc.
    Via Business Wire
    News headline image
    argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Host Autoimmune Myositis R&D Webinar
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Host Myositis R&D Webinar on June 23, 2026
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Present at Upcoming Investor Conferences
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Reports First Quarter 2026 Financial Results and Provides Business Update
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Present at BofA Securities 2026 Health Care Conference
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx announces Annual General Meeting of Shareholders on May 6, 2026
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
    From argenx SE
    Via GlobeNewswire
    News headline image
    argenx to Present at TD Cowen 46th Annual Healthcare Conference
    From argenx SE
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.